Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2.

Simon WoelfelJoel DütschlerMarius KönigNicole GrafVasileios OikonomouClaudia KriegerSamuel TrunigerAnnett FrankeAnnika EckholdKristina ForschJacqueline WyssNiklas KrupkaWerner AlbrichNicola FreiNora GeisslerPeter Schaubnull nullMatthias FriedrichBenjamin MisselwitzWolfgang KorteJustus J BürgiStephan Brand

Published in: Alimentary pharmacology & therapeutics (2022)

Anti-TNF-treated IBD patients have impaired humoral and cellular immunogenicity following SARS-CoV-2 booster vaccination. Fourth dose administration may be beneficial for these patients.

Keyphrases

sars cov
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
respiratory syndrome coronavirus
peritoneal dialysis
immune response
prognostic factors
patient reported
ulcerative colitis